SKB264 + KL-A167 + carboplatin

This is a combination therapy consisting of three agents for the treatment of cancer, primarily under investigation for advanced or metastatic non-small cell lung cancer (NSCLC) and HER2-negative breast cancer. - **SKB264** (also known as sacituzumab tirumotecan, MK-2870) is an antibody-drug conjugate (ADC) targeting TROP2 (trophoblast cell surface antigen 2), delivering a topoisomerase I inhibitor payload directly to TROP2-expressing tumor cells, causing DNA damage and tumor cell death. - **KL-A167** (tagitanlimab, Cotelet) is a fully humanized monoclonal antibody targeting programmed death-ligand 1 (PD-L1), functioning as a PD-L1 inhibitor to block the PD-1/PD-L1 immune checkpoint pathway and reverse tumor immune evasion. - **Carboplatin** is a platinum-based chemotherapy agent that induces DNA crosslinks, leading to apoptosis in rapidly dividing cells. The combination leverages tumor targeting (SKB264), immune checkpoint blockade (KL-A167), and cytotoxic chemotherapy (carboplatin) for a multi-pronged antitumor effect. Major clinical evaluation is ongoing for advanced NSCLC and HER2-negative breast cancer[3][5][7].

Brand names

Cotelet

Other names

tagitanlimabsacituzumab tirumotecan